Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 0.11%.

  • Protalix BioTherapeutics' Return on Capital Employed rose 2800.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11%, marking a year-over-year increase of 2800.0%. This contributed to the annual value of 0.07% for FY2024, which is 3500.0% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Return on Capital Employed stood at 0.11% for Q3 2025, which was up 2800.0% from 0.16% recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Return on Capital Employed high stood at 0.3% for Q3 2023, and its period low was 1.36% during Q2 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.22% (2021), whereas its average is 0.27%.
  • Per our database at Business Quant, Protalix BioTherapeutics' Return on Capital Employed plummeted by -14500bps in 2021 and then surged by 9700bps in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Return on Capital Employed (Quarter) stood at 0.45% in 2021, then decreased by -21bps to 0.55% in 2022, then soared by 147bps to 0.26% in 2023, then tumbled by -64bps to 0.09% in 2024, then grew by 16bps to 0.11% in 2025.
  • Its last three reported values are 0.11% in Q3 2025, 0.16% for Q2 2025, and 0.09% during Q1 2025.